Table 3.
Multivariable regression analysis of the association of HCV serostatus with the outcome of kidney transplantation, clustering on donor service area*
| Characteristic | Adjusted HR (95% CI) | |||||
|---|---|---|---|---|---|---|
| Death Censored N=39,873 |
Death as a Competing Risk N=39,873 |
Death or Delisting as a Competing Risk N=39,873 |
||||
| HCV-seropositive | 1.11 (0.97–1.28) | 1.10 | 0.96–1.27 | 1.12 | 0.99–1.28 | |
| Age≥40years | 0.83 | 0.78–0.88 | 0.77 | 0.73–0.82 | 0.82 | 0.77–0.87 |
| Male sex | 1.01 | 0.97–1.06 | 1.00 | 0.96–1.05 | 0.99 | 0.95–1.04 |
| Race | ||||||
| Caucasian | ref | ref | ref | |||
| African American | 0.61 | 0.55–0.66 | 0.66 | 0.61–0.72 | 0.71 | 0.66–0.77 |
| Latino | 0.66 | 0.54–0.80 | 0.73 | 0.61–0.88 | 0.80 | 0.67–0.95 |
| Asian | 0.51 | 0.38–0.68 | 0.56 | 0.43–0.75 | 0.61 | 0.46–0.81 |
| Other | 0.68 | 0.56–0.81 | 0.75 | 0.63–0.90 | 0.80 | 0.67–0.96 |
| BMI* | ||||||
| 18.5–30 kg/m2 | ref | ref | ref | |||
| <18.5 kg/m2 | 1.06 | 0.92–1.22 | 1.04 | 0.91–1.18 | 1.05 | 0.92–1.20 |
| 30–40 kg/m2 | 0.82 | 0.79–0.86 | 0.85 | 0.82–0.89 | 0.88 | 0.84–0.92 |
| >40 kg/m2 | 0.50 | 0.42–0.60 | 0.54 | 0.49–0.64 | 0.59 | 0.50–0.70 |
| PRA>80% | 0.74 | 0.66–0.83 | 0.73 | 0.65–0.82 | 0.73 | 0.65–0.82 |
| Blood group | ||||||
| O | ref | ref | ref | |||
| A | 1.69 | 1.60–1.79 | 0.64 | 1.55–1.73 | 1.57 | 1.49–0.66 |
| B | 1.07 | 1.00–1.13 | 1.05 | 1.00–1.11 | 1.04 | 0.99–1.10 |
| AB | 2.60 | 2.32–2.91 | 2.45 | 2.20–2.72 | 2.28 | 2.04–2.54 |
| Pre-WL dialysis, per 1-d longer | 1.00 | 1.00–1.00 | 1.00 | 1.00–1.00 | 1.00 | 1.00–1.00 |
| Diabetes mellitus | 0.80 | 0.76–0.84 | 0.74 | 0.71–0.78 | 0.72 | 0.68–0.76 |
| Liver disease | 0.98 | 0.84–1.14 | 0.97 | 0.83–1.14 | 0.96 | 0.83–1.12 |
| CVD | 0.91 | 0.84–0.99 | 0.89 | 0.82–0.96 | 0.88 | 0.83–1.12 |
| Income quintile ($US) | ||||||
| $8,993–35,363 | ref | ref | ref | |||
| $35,370–43,265 | 1.00 | 0.91–1.11 | 1.00 | 0.91–1.10 | 0.99 | 0.90–1.09 |
| $43,331–52,143 | 0.94 | 0.78–1.13 | 0.93 | 0.78–1.11 | 0.93 | 0.80–1.09 |
| $52,173–67,316 | 0.90 | 0.75–1.07 | 0.89 | 0.75–1.07 | 0.90 | 0.76–1.06 |
| $67,331–180,120 | 0.89 | 0.74–1.07 | 0.89 | 0.74–1.07 | 0.88 | 0.74–1.05 |
| Insurance | ||||||
| Medicare | ref | ref | ref | |||
| Medicaid | 0.99 | 0.87–1.13 | 1.02 | 0.89–1.15 | 1.04 | 0.92–1.18 |
| Private | 1.20 | 1.14–1.26 | 1.23 | 1.17–1.29 | 1.20 | 1.14–1.26 |
| Albumin <3.5 g/dL | 0.81 | 0.74–0.88 | 0.72 | 0.66–0.79 | 0.73 | 0.67–0.80 |
| Hemoglobin | ||||||
| <10 g/dL | 0.82 | 0.77–0.89 | 0.79 | 0.74–0.86 | 0.75 | 0.70–0.81 |
| 10–12 g/dL | 0.88 | 0.84–0.93 | 0.87 | 0.83–0.92 | 0.84 | 0.80–0.89 |
| >12 g/dL | ref | ref | ref | |||
| Platelets <150 × 103/mm3 | 0.99 | 0.93–1.04 | 0.94 | 0.89–1.00 | 0.95 | 0.89–1.00 |
Values shown are adjusted hazard ratio (95% confidence interval).
*
Body mass index from the day of wait-listing for kidney transplantation, as reported to the OPTN
Abbreviations: HR – Hazard ratio; CI – Confidence Interval; HCV – Hepatitis C virus; BMI – body mass index; PRA – panel reactive antibody; WL – Waitlist; CVD – cardiovascular disease; COPD – chronic obstructive pulmonary disease;